MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer.

ABSTRACT:

Purpose

Overexpression of miR-100 in stem cells derived from basal-like breast cancers causes loss of stemness, induction of luminal breast cancer markers and response to endocrine therapy. We, therefore, explored miR-100 as a novel biomarker in patients with luminal breast cancer.

Methods

miR-100 expression was studied in 90 patients with oestrogen-receptor-positive/human-epidermal growth factor receptor 2-negative breast cancer enrolled in a prospective study of endocrine therapy given either preoperatively, or for the treatment of de novo metastatic disease. Response was defined as a Ki67 ≤2.7% after 21±3 days of treatment. The prognostic role of miR-100 expression was evaluated in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer

SUBMITTER: Petrelli A 

PROVIDER: S-EPMC7597498 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature